Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD

Go back to Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD

DA Davidson Reiterates Neutral Rating on Barnes Group (B)

October 28, 2024 4:05 PM EDT

DA Davidson analyst Matt Summerville reiterated a Neutral rating and $47.50 price target on Barnes Group (NYSE: B).

The analyst comments "Last Friday, Barnes reported 3Q24 results with its overall performance summarized below. With the pending takeout by Apollo Global subject to No-Shop... More